LABIANA HEALTH S.A.EO-10 - Asset Resilience Ratio
LABIANA HEALTH S.A.EO-10 (8RK) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LABIANA HEALTH S.A.EO-10 short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how LABIANA HEALTH S.A.EO-10's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see LABIANA HEALTH S.A.EO-10 asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down LABIANA HEALTH S.A.EO-10's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read LABIANA HEALTH S.A.EO-10 balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.80K | 0.0% |
| Total Liquid Assets | €1.80K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: LABIANA HEALTH S.A.EO-10 maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
LABIANA HEALTH S.A.EO-10 Industry Peers by Asset Resilience Ratio
Compare LABIANA HEALTH S.A.EO-10's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for LABIANA HEALTH S.A.EO-10 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for LABIANA HEALTH S.A.EO-10.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | €1.80K ≈ $2.10K |
€57.54 Million ≈ $67.27 Million |
+0.00pp |
| 2024-12-31 | 0.00% | €800.25 ≈ $935.58 |
€52.00 Million ≈ $60.80 Million |
-0.02pp |
| 2023-12-31 | 0.02% | €13.94K ≈ $16.30K |
€59.12 Million ≈ $69.12 Million |
+0.01pp |
| 2022-12-31 | 0.01% | €9.10K ≈ $10.64K |
€60.78 Million ≈ $71.06 Million |
0.00pp |
| 2021-12-31 | 0.02% | €11.45K ≈ $13.38K |
€68.37 Million ≈ $79.93 Million |
-- |
About LABIANA HEALTH S.A.EO-10
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, North America, and internationally. It offers anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, and vitamin products. The company also provides sterile and lyophilized dosage f… Read more